Heluo Xintu Biotech Secures Tens of Millions in Angel Funding Led by Kaitai Capital to Advance iPSC-Based Cell Therapy Platform

Investment Circle (ID: pedaily2012) April 26th, by reporter [Name]. Recently, Renerval Therapeutics announced the completion of a financing round led byKaitai CapitalLed byTens of Millions of Angel RoundFinancing. The funds raised in this round will be mainly used for the construction of a cell therapy platform based on induced pluripotent stem cells (iPSC), team enhancement, and business expansion, promoting the rapid transformation of the company's technology development from laboratory to industrialization.

Renerval Therapeutics was founded in 2021. The founding team is led by returning scholars from the Massachusetts Institute of Technology and the University of Cambridge. It is a high-tech innovative enterprise focused on iPSC directed differentiation, gene editing, large-scale cell product preparation, and cell therapy technology development.

Dr. Wang Wenyuan, Founder of Renerval Therapeutics"It is an inevitable trend in the development of pharmaceutical R&D to make 'living cells' a powerful remedy for treating diseases that threaten human life and health. It is also the steadfast direction of our company's development. Hangzhou Kaitai Capital Management Ltd. has a profound understanding of and visionary layout in the biopharmaceutical industry. We are highly honored that our R&D capabilities and development potential have been recognized by Kaitai Capital. We are especially grateful for their unwavering support even amid the current pandemic-related lockdowns, which has deeply moved me and my team. This support further strengthens our confidence in innovating, forging ahead, and realizing the company vision of 'rejuvenating cells and saving lives with cells.'"

Kaitai Capital"One generation of technology, one generation of industry, one generation of entrepreneurs, and one generation of investors. The biopharmaceutical industry is no exception, from small-molecule chemical drugs to antibody drugs, we are now embracing the third wave of modern pharmaceuticals—currently booming nucleic acid drugs—accompanied by novel therapies such as gene and cell therapies."

Investment only cares about one thing: What is the future? In the biopharmaceutical field, the future belongs to the era of nucleic acid drugs, gene therapy, and cell therapy. Based on the long-term tracking and research by our biopharmaceutical and biotechnology team in the direction of cell and gene therapy, induced pluripotent stem cells (iPSC) are one of our key focuses. We are optimistic about the technological maturity and application prospects of induced pluripotent stem cells.

Kaitai Capital Invests in Renerval Therapeutics, Aiming to Bring Induced Pluripotent Stem Cell Technology to the Blood Products Field and Explore Drug Delivery Technologies, Driving the Widespread Application of Induced Pluripotent Cells in More Disease Areas with the Power of Innovative Capital to Benefit More Lives and Improve Health.

This article is sourced from Investment Circle, author: Chen Yujin, original text: https://news.pedaily.cn/202204/491009.shtml